Medarex, a biopharmaceutical company headquartered in Princeton, NJ, focuses on discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases.

Thirty-four therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with six of the most advanced product candidates currently in Phase III clinical trials.

The company's leading biologic is:

*Information above taken from materials provided by Medarex..